Knowledge on mechanisms involved in early prediction of response to antidepressant medication may help optimize clinical decision making. Recent studies regarding response to pharmacotherapy implicate resilience-like mechanisms and involvement of positive, rather than negative emotions. The aim of the current study is to examine the contribution of early change in positive affect to the prediction of response to pharmacotherapy. Positive and negative emotions were measured at baseline and during the first week of pharmacotherapy, using experience sampling techniques. The association between early change in positive and negative emotions and severity of depressive symptoms at week six was examined in a sample of 49 depressed patients. The added benefits of measuring early change in positive emotions compared to early Hamilton Depression Rating Scale (HDRS) change alone were evaluated through model comparisons. Early improvement in positive affect during the first week of treatment predicted the continuous HDRS score (β = −0.64, p b 0.001), response (50% reduction; OR =4.32, p b 0.01), and remission (HDRS ≤ 7; OR =9.29, p b 0.001) at week six with moderate to large effect sizes. Effects of early change in negative emotions were only half as large and disappeared when evaluated simultaneously with early change in positive emotions. When early change in positive emotions was added to the models including early HDRS change only, all three models improved significantly. In conclusion, early change in positive rather than negative emotions best predicted response to treatment, supporting the notion that antidepressants activate resilience-like mechanisms. Moreover, monitoring of positive emotions in early stages of treatment may improve clinical decision making.
Introduction
The efficiency of depression treatment can be considerably improved if current trial and error strategies are enriched with accurate outcome predictors at an early stage of treatment. In contrast to previous hypotheses on delayed onset of treatment response (Quitkin et al., 1984) , evidence suggests that about 60% of the improvement occurring on active antidepressant and placebo takes place during the first two weeks of treatment (Posternak and Zimmerman, 2005) . Several randomized or naturalistic studies as well as meta-analyses have shown that early improvement after one or two weeks of treatment strongly predicts later treatment outcome (e.g., Henkel et al., 2009; Stassen et al., 2007; Szegedi et al., 2009; Tadic et al., 2010) . However, all these studies on early improvement assessed symptom severity with the Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) . The HDRS is a multidimensional instrument that covers only a selected number of clinical symptoms and neglects the assessment of positive emotions (Bagby et al., 2004) . Investigations that rely on the HDRS therefore provide little information on the nature of emotional changes driving long-term improvement in early responders. Better knowledge on the emotional mechanisms involved in early response may aid the development of better strategies for assessing early response to treatment, thereby optimizing clinical decision making and improving quality of life for patients suffering from depression.
Although studies show that antidepressant use affects both positive and negative emotion processing (e.g. Harmer et al., 2010; Rawlings et al., 2010) , recent studies suggest that changes in positive rather than negative emotions may be important in predicting recovery from depression. First, recovery from depression was associated with increases in the ability to experience reward in daily life, rather than decreases in sensitivity to stress (Wichers et al., 2009 ). Second, a high ability to experience positive emotions in daily life was associated with both reduced risk of becoming depressed in individuals with high genetic loading for depression and increased resilience against the development of affective symptoms Wichers et al., 2007 Wichers et al., , 2010 . Third, Stassen et al. (2007) concluded that antidepressants appear to trigger and maintain a common, resilience-like mechanism that controls recovery from depression. Psychological resilience can be defined as the ability to bounce back from negative emotional experiences (Block and Kremen, 1996; Tugade and Fredrickson, 2004) , and recent studies show that positive, but not negative emotions, predict psychological resilience (Cohn et al., 2009) .
Based on the findings outlined above, we hypothesized that early change in positive affect, rather than early change in negative affect, would be an important predictor of response to antidepressant treatment. Furthermore, we expected that adding information on early change in positive affect to information on early change in HRSD would significantly improve early prediction models of recovery from depression. We tested this hypothesis in a pre-existing longitudinal dataset on depressed patients starting pharmacotherapy. Early change in positive and negative emotions was measured using the experience sampling method (ESM) at baseline and at the end of the first week of pharmacotherapy. ESM is a momentary assessment technique in which participants are prompted to report on current emotions at random moments during the day, and is ideally suited for investigating change in emotions in daily life (Csikszentmihalyi and Larson, 1987) .
Experimental procedures

Sample
Eighty-three patients with a DSM-IV diagnosis of current major depressive disorder (MDD) were recruited in eight primary care practices in the Netherlands (for full details concerning diagnosis and screening, see Barge-Schaapveld and Nicolson, 2002) . Data were collected in the period between 1995 and 1996. Inclusion criteria were aged between 18 and 65 years and a score at study entry of ≥ 18 on the 17-item Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) . Exclusion criteria included major medical disorders and current use of psychotropic medications, except for the occasional use of temazepam. All participants gave written informed consent. The study was approved by the standing medical ethics committee.
Study design
During an initial baseline week, participants received no treatment in any form and took part in the experience sampling procedure during 6 days. Those who had completed at least 30 valid experience sampling assessments (for rationale see Experience sampling method below) were randomly assigned to twice-daily, double-blind, sixweek treatment with either a tricyclic antidepressant or placebo (imipramine: starting dose of 50 mg/day, increased to 200 mg/day over the first week of treatment; placebo: starting with one capsule per day, increased to 4 capsules over the first week of treatment). In case of intolerance, the dose could be decreased to either 100 mg/day of imipramine or 2 placebo capsules per day. Participants then took part in a second period of experience sampling during the last three days of the first week of treatment. In addition, patient's general practitioners (GPs) administered the HDRS at screening, and at the end of baseline, week 1, week 2, week 4 and week 6. The current report used data from baseline, week 1 and week 6.
Experience sampling method
The experience sampling method (ESM) is a momentary assessment method to assess participants in their daily living environment, providing repeated in-the-moment assessments of affect in a prospective and ecologically valid manner (Csikszentmihalyi and Larson, 1987) . Participants received a digital wristwatch and a set of ESM self-assessment forms collated in a booklet for each day. The wristwatch was programmed to emit a signal ("beep") at an unpredictable moment in each of ten 90-minute time blocks between 7:30 and 22:30, on consecutive days, resulting in a maximum of 60 beeps per person for the baseline measurement and a maximum of 30 beeps for the last three days of the first week. After each beep, participants were asked to fill out the ESM self-assessment, collecting reports of current mood and context. All self-assessments were rated on 7-point Likert scales. Participants were instructed to complete their reports immediately after the beep, thus minimizing memory distortion, and to record the time at which they completed the form. Participants with less than one third of valid reports were excluded from the analysis, and all reports not completed within 15 min after the actual beep were considered invalid, as previous work (Delespaul, 1995) has shown that reports completed after this interval are less reliable and consequently less valid.
Measurements 2.4.1. Hamilton Depression Rating Scale (HDRS)
The 17-item HDRS (Hamilton, 1960) was administered by the treating GP. All participating GPs had completed a standardized training for the HDRS.
Positive affect (PA) and negative affect (NA)
At each beep, several ESM mood adjectives were assessed on 7-point Likert scales ranging from 1 (not at all) to 7 (very), as described previously (Barge-Schaapveld and Nicolson, 2002) . The mood adjectives 'cheerful', 'satisfied, 'energetic', 'calm', 'enthusiastic', 'strong' and 'happy' loaded on the PA factor (Cronbach's alpha= 0.89), whereas 'hostile', 'depressed', 'tense', 'insecure', 'lonely', 'anxious', 'guilty', 'harried' and 'irritable' loaded on the NA factor (Cronbach's alpha =0.85). Mean levels of PA and NA were computed for each participant at each study period (baseline or end of week one) separately.
Statistical analysis 2.5.1. Definitions of early change
Early changes in HDRS, NA and PA were computed as the difference between the measure at baseline and at the end of week one, such that positive values reflect improvement (week one minus baseline for HDRS and NA change, baseline minus week one for PA change).
Definitions of response and remission
In agreement with commonly used definitions (e.g., Ballesteros et al., 2007; Henkel et al., 2009) , response was defined as a reduction of 50% or more in HDRS score from baseline to week 6, and remission as a score of 7 or less on the HDRS at week 6. 
Statistical tests
Contributions of early change in PA and NA to improvement by week 6 were examined separately, using three different definitions of improvement: the continuous HDRS score at week 6, response, and remission. Simple linear regression with covariates was used to analyze the relationship of early change in PA and NA, respectively, with the continuous HDRS score at week 6, while correcting for baseline HDRS score. Logistic regression was used for the dichotomous outcomes response and remission. Because of our specific hypotheses on the importance of PA, further analyses focussed on early change in PA.
Analyses explored to what extent early improvement in PA (compared to early deterioration or no change in PA) predicted improvement at week 6. Likelihood ratio tests were used to test whether early change in PA provided additional information over and above early HDRS change.
Imipramine and placebo groups were analyzed together, because mechanisms and trajectories of recovery have been found to be similar for antidepressant medication and placebo (Papakostas et al., 2006; Posternak and Zimmerman, 2005; Stassen et al., 2007) . Analyses were, however, corrected for group status (imipramine vs. placebo) and repeated in each group separately to verify the assumption that early change in PA predicted recovery from depression similarly in the placebo and TCA group.
Because average levels of affect at baseline influence the extent of possible change in PA or NA (i.e., ceiling or floor effects), all analyses were corrected for participant's average PA or NA at baseline. All variables were standardized, except for the outcome variables remission and response in the logistic regression. Standardized regression coefficients β are reported for the linear regressions, and Odd's Ratios (OR) for the logistic regressions. Analyses were performed in Stata 11 (StataCorp, 2009 ).
Results
Participant characteristics
Of the 83 recruited patients, 9 were excluded on the basis of the described inclusion and exclusion criteria. Additional 11 patients completed fewer than 30 valid ESM reports at baseline, which was the pre-set criterion for study continuation. Forty-nine of the remaining 63 participants (78%) completed the first 6 weeks of treatment. Seventeen of the 49 participants received imipramine, and 22 placebo. Analyses were based solely on data of participants who completed treatment. Dropouts showed a trend towards higher PA at baseline, compared to completers (β = 0.31, p =0.09). There were no other significant baseline differences between dropouts and completers, and dropout was not associated with treatment group (imipramine vs. placebo).
Participants ranged in age from 25 to 59 years (mean=42.5, SD =9.2). The majority were female (73%) and married (69%). Most had regular jobs (47%) or were housewives (27%). Average HDRS score ranged from 19 to 30 at baseline and from 0 to 24 at week 6. Sixteen out of 49 participants were in remission in week 6, and 30 were classified as responders. Means and standard deviations of PA, NA, and HDRS scores by study period are presented in Table 1 . Only 10 out of 49 participants (5 in the imipramine group, and 5 in the placebo group) experienced improvement of PA in the first week (defined as PA week 1 N PA baseline), with no change or worsening in the others. Participants with early improvement of PA did not differ from the other participants in terms of socio-demographic characteristics and severity of depression (all pN .20). Fig. 1 displays average changes in PA, NA, and HDRS during the first week of treatment, overall and stratified by response and remission status at week 6.
Association of early change in PA and NA with recovery from depression
Early change in PA during the first week of treatment significantly predicted continuous HDRS scores as well as response and remission at week six. As shown in Table 2 , effect sizes of early change in PA were moderate to large. Expressed in unstandardized values, an increase of one point (on the 7-point Likert scale) in PA from baseline to week one corresponded to a 4-point decrease on the HDRS by week six. Experiencing early improvement of PA, compared to no change or early worsening of PA, was associated with a 9-point decrease on the HDRS in week six (β=−0.54, pb 0.001) and a 34 times higher probability of achieving remission (OR = 33.90, pb 0.01). All 10 participants with early improvement of PA met the response criterion at week six. Effect sizes of early change in PA remained moderate to large when the analyses were repeated separately for the placebo group (continuous: β= −0.54, pb 0.01, response: OR =3.89, pb 0.05, remission: OR =6.52, pb 0.05) and the imipramine group (continuous: β = −0.63, p b 0.01, response: OR =5.38, p=0.07, remission: OR =20.41, pb 0.05).
Although early change in NA also was a significant predictor for the continuous HDRS sore and remission status (but not for 1 We chose to focus the analysis on outcome measures at week 6 because this is a clinically relevant time frame in which one can expect major changes in depressive symptoms. However, all analyses yielded similar results when repeated using definitions of stable response (50% reduction at both week 4 and week 6) and stable remission (≤7 at week 4 and week 6), or when a growth model was used instead of linear regression analyses. response) at week 6, effect sizes were only about half the size of those for early change in PA (see Fig. 2 ). When early change in PA and early change in NA were entered simultaneously to check for the independence of their contributions, effect sizes of early change in PA remained significant and similar in size (continuous: β = −0.57, p b 0.001, response: OR = 4.00, p b 0.05, remission: OR = 6.94, p b 0.01), while the effects of early change in NA decreased and were no longer statistically significant (continuous: β = −0.12, p N .3, response: OR = 1.32, p N .4, remission: OR = 1.62, p N .4), indicating that the predictive value of NA is reducible to that of PA.
Improvement of early prediction models through addition of early change in PA
Early change in HDRS predicted significant improvement on all three outcome measures (continuous: β = −0.48, p b 0.001, response: OR =4.08, p b 0.05, remission: OR =2.36, p b 0.05). When early change in PA was added to the model including early change in HDRS, all three models improved significantly (continuous: chi2 (2) = 12.90, p b 0.01; response: chi2(2) = 6.24, p b 0.05; remission chi2(2) = 14.72, p b 0.001), with the proportion of explained variance increasing from 30% to 44%, from 18% to 28%, and from 16% to 40%, respectively.
Discussion
Early change in positive affect (PA), compared to negative affect (NA), best predicted response to treatment. Early change in PA during the first week of treatment was associated with improvement on the Hamilton Depression Rating Scale (HDRS), response (50% symptom reduction), and remission (HDRS ≤7) at week six. Effect sizes were moderate to large. Early change in NA was not consistently associated with response to treatment, and effect sizes were much smaller than those of early change in PA. When both predictors were entered into the regression model simultaneously, the effects of NA change diminished even further, whereas effect sizes of early change in PA remained similar. Compared to no change or early worsening of PA, experiencing early improvement of PA was associated with a 34 times higher chance of achieving remission, and all 10 participants with early improvement of PA achieved response at week six. Early PA improvement did not depend on treatment group (imipramine or placebo). Because participants with early improvement of PA did not differ from the other participants in terms of socio-demographic characteristics and severity of depression, differences in outcome can likely be attributed to changes in PA, rather than to third variables associated with PA. Finally, adding early change in positive emotions to standard early prediction models significantly improved accuracy of prediction at week six for all three outcome measures.
In order to speed up recovery from depression and provide adequate treatment, it is useful to identify non-responders as early and as accurately as possible. Early change in PA provided vital information for prediction of response over and above early HDRS change, which is still used as gold standard for the assessment of depression, despite psychometrical and conceptual flaws (Bagby et al., 2004) . The HDRS unfortunately Table 1 Means and standard deviations (in brackets) of positive affect (PA), negative affect (NA) and Hamilton Depression Rating Scale (HDRS) scores in the overall sample, and stratified by response and remission status. does not measure PA at all. It contains only one item on "Work and Interest", in which patients' capacity to work is assessed simultaneously with their hospitalization status and levels of interest in activities (Hamilton, 1960) . We argue that assessment of PA may aid early identification of (non)response and that assessment of PA should be included when monitoring early treatment response. More research is needed before determining clinically informative cut-off points which eventually could be used to aid clinical decision making involved in the treatment of depression. Another unanswered question is which time frame is best for assessing early changes in PA. Early improvement in this study was very successful in identifying responders to treatment (i.e., all early PA improvers met the response criterion at week six). However, the low rate of early PA improvement (compared to reported rates of 65% of early HDRS improvement; Szegedi et al., 2009) may mean that measuring PA change after two weeks could be more successful in identifying non-response and need for adjustment of treatment.
Because studies indicate that PA is associated with resilience and well-being more strongly than NA (e.g., Cohn et al., 2009; Fredrickson et al., 2003) , our findings support Stassen et al.'s (2007) claim that antidepressant treatment may activate resilience-like mechanisms. Earlier studies found that positive emotions were associated with attenuated expression of genetic risk for depression and increased resilience after adversity Wichers et al., 2008 Wichers et al., , 2007 Wichers et al., , 2010 . Furthermore, in an experimental setup, depressed participants differed from healthy controls only regarding emotional response to anticipated reward but not punishment (McFarland and Klein, 2009) . The current study adds to the accumulating evidence on the importance of positive emotions in depression by showing that, after as early as one week of treatment, the PA system reacts sensitively to treatment and is closely linked to later response. Whether PA is part of the resilience response or rather facilitates action of other resilience-related mechanisms remains unclear and may be investigated in future research.
Several large studies as well as meta-analyses demonstrate that trajectories of recovery under active antidepressantsonce triggered -follow a pattern similar to that of placebo, despite marked pharmacologic differences of the triggers (Posternak and Zimmerman, 2005; Stassen et al., 2007; Szegedi et al., 2009; Tadic et al., 2010) . Also in the current study, early change in PA predicted response to treatment in both the imipramine and the placebo group, implying overlapping mechanisms of recovery from depression in both groups. As Stassen et al. (2007) argue, this may mean that depressed patients have a biological resilience-like predisposition that controls the time course of recovery and that can be triggered, modified or suppressed. Our study suggests that drugs -or psychotherapies -actively targeting the PA or reward system may be particularly effective in activating resilience mechanisms leading to recovery from depression. Drugs that modulate catecholaminergic activity may increase PA more than other types of drugs (Depue et al., 1994; Nutt et al., 2007) because they tend to elevate dopamine activity in the prefrontal cortex (Karson et al., 1983) . Tugade and Fredrickson (2004) , for example, reported that the catecholaminergic action of bupropion SR produced more robust effects on anhedonia than placebo (although see Dichter et al., 2005) . It is possible that drugs that facilitate early changes in PA are more efficient in triggering recovery processes, even though these differences in PA may disappear as time goes by and patients recover from depression.
In conclusion, the involvement of positive emotions in early response to antidepressant treatment supports the activation of resilience-like mechanisms in recovery from depression. Moreover, monitoring of positive emotions in early stages of treatment may improve clinical decision making.
Limitations of the study include that evaluation of response and remission took place in week 6. Our results need to be replicated in studies with longer follow-up periods and larger samples. Another limitation is that follow-up measurements of dropouts were unavailable, possibly distorting the results. However, analyses are likely to underestimate rather than overestimate the effects of early PA improvement, given that 10 of 11 dropouts were participants with non-improvement of PA. Finally, the relatively small sample size only allowed for investigations of mechanisms of change common to placebo and active antidepressant medication. However, several large studies suggest that early improvement mechanisms appear to be similar in placebo and active drugs (e.g., Stassen et al., 2007; Szegedi et al., 2009) , and early change in positive affect was an important predictor of improvement also when both groups (placebo and imipramine) were examined separately.
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